Elite in Oligodendroglioma

Ahmed Idbaih

Paris, FR 
Elite in Oligodendroglioma
Paris, FR 
OverviewLocationsClinical Research

Overview

Ahmed Idbaih practices in Paris, France. Mr. Idbaih is rated as an Elite expert by MediFind in the treatment of Oligodendroglioma. His top areas of expertise are Glioma, Gliomatosis Cerebri, Astrocytoma, Glioblastoma, and Tissue Biopsy.

His clinical research consists of co-authoring 270 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 31 articles in the study of Oligodendroglioma.

Gender
Male

Locations

Paris, 75013, France
Other Locations
Marseille, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase III Trial of Marizomib in Combination With Standard Temozolomide-based Radiochemotherapy Versus Standard Temozolomide-based Radiochemotherapy Alone in Patients With Newly Diagnosed Glioblastoma
A Phase III Trial of Marizomib in Combination With Standard Temozolomide-based Radiochemotherapy Versus Standard Temozolomide-based Radiochemotherapy Alone in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Completed
Publish Date: July 01, 2025
Intervention Type: Drug, Radiation
Study Drugs: Marizomib, Temozolomide
Study Phase: Phase 3
A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
Enrollment Status: Active_not_recruiting
Publish Date: May 04, 2025
Intervention Type: Drug
Study Drugs: Berubicin, Lomustine
Study Phase: Phase 2
View 1 Less Clinical Trial

270 Total Publications

Neurocognitive impairment and patient-proxy agreement on health-related quality of life evaluations in recurrent high-grade glioma patients.
Neurocognitive impairment and patient-proxy agreement on health-related quality of life evaluations in recurrent high-grade glioma patients.
Journal: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
Published: April 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Idbaih's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 32 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile